0001493152-22-032664.txt : 20221116 0001493152-22-032664.hdr.sgml : 20221116 20221116172629 ACCESSION NUMBER: 0001493152-22-032664 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221116 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221116 DATE AS OF CHANGE: 20221116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vyant Bio, Inc. CENTRAL INDEX KEY: 0001349929 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 043462475 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35817 FILM NUMBER: 221396189 BUSINESS ADDRESS: STREET 1: 2370 STATE ROUTE 70 WEST STREET 2: SUITE 310 CITY: CHERRY HILL, STATE: NJ ZIP: 08002 BUSINESS PHONE: 201.528.9200 MAIL ADDRESS: STREET 1: 2370 STATE ROUTE 70 WEST STREET 2: SUITE 310 CITY: CHERRY HILL, STATE: NJ ZIP: 08002 FORMER COMPANY: FORMER CONFORMED NAME: CANCER GENETICS, INC DATE OF NAME CHANGE: 20111216 FORMER COMPANY: FORMER CONFORMED NAME: CANCER GENETICS INC DATE OF NAME CHANGE: 20060117 8-K 1 form8-k.htm
0001349929 false 0001349929 2022-11-16 2022-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 16, 2022

 

VYANT BIO, INC.

(Exact Name of Company as Specified in its Charter)

 

Delaware   001-35817   04-3462475

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

2 Executive Campus

2370 State Route 70, Suite 310

Cherry Hill, NJ 08002

(Address of Principal Executive Offices) (Zip Code)

 

Company’s telephone number, including area code (201) 479-8126

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   VYNT   The Nasdaq Capital Market

 

Indicate by check mark whether the Company is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD.

 

On November 16, 2022, Vyant Bio, Inc. (the “Company”) issued a press release announcing that the Company made two platform and poster presentations during the Rett Nanosymposium at Neuroscience 2022, hosted by the Society for Neuroscience, which was held November 12th-16th at the San Diego Convention Center. A copy of the press release is attached hereto as Exhibit 99.1.

 

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

As described above, the following exhibits are furnished as part of this report:

 

Exhibit No.   Description
     
99.1   Press Release issued by Vyant Bio, Inc., dated November 16, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    VYANT BIO, INC.
       
Date: November 16, 2022 By: /s/ John A. Roberts
    Name: John A. Roberts
    Title: President and Chief Executive Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at Neuroscience 2022 Hosted by the Society for Neuroscience

 

“Targeting specific functional rescue in a Rett patient cortical organoid disease model”

 

CHERRY HILL, N.J., November 16, 2022 (GLOBE NEWSWIRE) — Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning to identify and validate drug targets and therapeutic candidates. Today, Vyant Bio made two platform and poster presentations during the Rett Nanosymposium at Neuroscience 2022, hosted by the Society for Neuroscience, which was held November 12th-16th at the San Diego Convention Center. In the first presentation, the Company announced the identification of a therapeutic candidate for Rett syndrome with a differentiated mechanism of action advancing into clinical trials. In the second, the Company presented a multiparametric analysis of coordinated network activity revealing target-specific functional rescue in a human iPSC-derived organoid model of Rett syndrome. The presentations were delivered, respectively, by Cassiano Carromeu, PhD, Vyant Bio’s Director of R&D, and Andrew LaCroix, PhD, Vyant Bio’s Lead Screening Scientist.

 

Title: Identification of a therapeutic candidate for Rett syndrome with a differentiated mechanism of action using a patient-derived cortical organoid screening platform

 

Authors: Cassiano Carromeu (Presenting), Nicholas Coungeris, Neha Sodhi, Huda Ahmed, Megan Seibel, Kendra Prum, Robert Fremeau, and Andrew LaCroix

 

Session: Rett Syndrome

 

Date / Time: November 16, 2022: 9:00 am PT

 

Title: Multiparametric analysis of coordinated network activity reveals target-specific functional rescue in a human iPSC-derived organoid model of Rett syndrome

 

Authors: Andrew LaCroix (Presenting), Huda Ahmed, Nicholas Coungeris, Cameron Joseph, Neha Sodhi, Cassiano Carromeu, Robert Fremeau

 

Session: Rett Syndrome

 

Date / Time: November 16, 2022: 9:30 am PT

 

The platform presentations can be found at: https://www.vyantbio.com/.

 

 

 

 

Rett syndrome (RTT) is a progressive neurodevelopmental disorder caused by mutations in the X-linked gene MECP2. One of the challenges developing therapeutics for RTT has been the lack of a screening system that recapitulates the underlying human disease pathophysiology. Vyant Bio developed an in vitro human RTT cortical organoid platform that exhibits abnormal functional neuronal network activity that can be recorded in high-throughput, providing a stable foundation for high-throughput drug screening. Functional screening of a targeted compound library developed for RTT by the International Rett Syndrome Foundation (IRSF) identified several known inhibitors of acetylcholinesterase (AChE) and histone deacetylases that rescued the functional RTT disease phenotype. Vyant Bio further explored the rescue potential of donepezil, an FDA-approved compound that we prioritized as a potential repurposing candidate for RTT, VYNT 0126. Donepezil rescued the RTT disease phenotype at concentrations known to be achieved in the human brain after chronic treatment correlating with near complete AChE inhibition. These findings are consistent with literature support for cholinergic deficits in RTT patients and donepezil-based rescue in a mouse RTT model (reviewed in Ballinger et al., 2019). The Company observed that donepezil appears to exhibit a distinct mechanism of action from the most advanced RTT clinical development candidates. Based on these findings, Vyant Bio, with the support and encouragement of the Clinical Trial Committee of the International Rett Syndrome Foundation (IRSF) is pursuing the clinical development of donepezil for the treatment of pediatric and adult RTT patients with a mutation in the MECP2 gene.

 

Dr. Robert T. Fremeau, PhD, Vyant Bio’s Chief Scientific Officer, said “we are excited by the opportunity to present our proprietary CNS drug discovery platform to one of the premiere gatherings of scientists and physicians specializing in the area of neuroscience research and innovation. By utilizing our proprietary CNS drug discovery platform, we will be able to successfully demonstrate that we can identify and validate drug targets and therapeutic candidates for the treatment of complex neurodevelopmental and neurodegenerative disorders. I am pleased to announce that on November 14, 2022 we submitted a clinical trial application with the Alfred Hospital Human Research Ethics Committee (HREC) to conduct a phase 2 proof-of-concept clinical trial for VYNT-0126 in adult RTT patients in Australia. In addition, we received acknowledgment that the FDA has accepted our request for a pre-IND meeting, to provide feedback and guidance for our clinical development plan for this program by December 27, 2022. These represent important milestones for Vyant Bio as we strive to establish the value of our proprietary CNS drug discovery platform to discover novel therapeutics for CNS genetic diseases that can potentially halt disease progression or perhaps, even cure disease.”

 

ABOUT THE SOCIETY FOR NEUROSCIENCE

 

The Society for Neuroscience is a professional society, headquartered in Washington, DC, for basic scientists and physicians around the world whose research is focused on the study of the brain and nervous system. It is especially well known for its annual meeting, consistently one of the largest scientific conferences in the world.

 

 

 

 

ABOUT VYANT BIO, INC.

 

Vyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq: VYNT) is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapeutics for treating the debilitating neurodevelopmental and neurodegenerative disorders for which there are no current therapies. Vyant Bio has built a platform of therapeutics seeking to treat neurodevelopmental and neurodegenerative diseases, with current programs targeting Rett Syndrome (“Rett”), CDKL5 Deficiency Disorders (“CDD”), and familial Parkinson’s Disease. The Company’s approach to drug discovery integrates human-derived biology with artificial intelligence and machine learning technologies to de-risk candidate selection, with the goal of improving the potential effectiveness of drugs discovered earlier in the development cycle. Vyant Bio’s management believes that drug discovery needs to progressively shift to more efficient methods as the widely used models for predicting safe and effective drugs have under-performed, as evidenced by the significant time and cost of bringing novel drugs to patients. By combining sophisticated data science capabilities with highly functional human cell derived disease models, Vyant Bio seeks to leverage its current ability to screen and test therapeutic candidates, and create a unique approach to assimilating data that supports decision making iteratively throughout the discovery phase of drug development to identify both novel and repurposed CNS therapeutic candidates.

 

For more information, please visit or follow Vyant Bio at:

 

Internet: www.vyantbio.com
LinkedIn: https://www.linkedin.com/company/vyant-bio
Twitter: @VyantBio

 

Forward Looking Statements:

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.’s expectations regarding future financial and/or operating results, the efficacy of our drug screening and discovery process, and potential for our services, future revenue or growth in this press release constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to discover drug candidates, partner with pharmaceutical and other biotechnology companies, achieve profitability, adapt to the global coronavirus pandemic, raise capital to meet our liquidity needs, and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2021, and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio disclaims any obligation to update these forward-looking statements.

 

Investor Contact:

 

Skyline Corporate Communications Group, LLC

Scott Powell, President

One Rockefeller Plaza, 10th Floor

New York, NY 10020 USA

Office: (646) 893-5835 x2

Email: info@skylineccg.com

 

###

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 vynt-20221116.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 vynt-20221116_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 vynt-20221116_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Nov. 16, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 16, 2022
Entity File Number 001-35817
Entity Registrant Name VYANT BIO, INC.
Entity Central Index Key 0001349929
Entity Tax Identification Number 04-3462475
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2 Executive Campus
Entity Address, Address Line Two 2370 State Route 70
Entity Address, Address Line Three Suite 310
Entity Address, City or Town Cherry Hill
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08002
City Area Code 201
Local Phone Number 479-8126
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol VYNT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001349929 2022-11-16 2022-11-16 iso4217:USD shares iso4217:USD shares 0001349929 false 8-K 2022-11-16 VYANT BIO, INC. DE 001-35817 04-3462475 2 Executive Campus 2370 State Route 70 Suite 310 Cherry Hill NJ 08002 201 479-8126 false false false false Common Stock VYNT NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $V+<%4'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !-BW!56;;[R>T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)OI\E*#Z';B^))07!!\1:2V=U@TX1DI-VW-XV[740?P&-F_GSS M#4RG@]0^XG/T 2-93#>S&\8D==BR(U&0 $D?T:E4Y\28FWL?G:+\C <(2G^H M X)HFA8,V!]&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M38MP5=;%E_1L! KQ$ !@ !X;"]W;W)K':&!YN;:Z0MA"]"<+;FR'.#; M=V6(3:]F35X$R_8^_GFU?E9V;ZOTMW3#N2&[.))IW]D8D]R[;AIL>,S26Y5P M"4=62L?,P%"OW331G(5Y4!RYU/-:;LR$= :]?-],#WHJ,Y&0?*9)FL4QT_L' M'JEMW_&=]QTO8KTQ=H<[Z"5LS>?<_)',-(S<0B44,9>I4))HONH[0__^@;9L M0'[&J^#;]&2;V%M9*O7-#B9AW_$L$8]X8*P$@Y\W/N)19)6 XY^CJ%- M;K^K/^4W#S>S9"D?J>B+",VF[W0<$O(5RR+SHK8?^/&&[JQ>H*(T_T^VAW.; M38<$66I4? P&@EC(PR_;'1-Q$D"],P'T&$!S[L.%N>:T#*[G"#8]C#(8R>"9NJMUOBMZX)]2C] M;[@+! 4&+3!HKM? ,,A?PV5J-$S4WU5$!X5FM8*MWOLT80'O.U">*==OW!G\ M^(/?\GY!^!H%7P-3'SRJ((-:-&2Q3W@5'![>N?F(0#0+B":J,@2",*=XBMBZ MB@*/7[$HY0C'7<%Q=UDR9EP+%9*Q# D47V5><*6BC.KJJ%6@M5#!L33"[,F3 MB#B99O&RNK9Q#<_S;QIW';^-\+0+GO8E/"]\+6QE0\ZF+*Y,%*[S^G4X75P] M3)ZOR60ZND7(.@59YQ*R$^KV+#E3Q(6*/9[=(N@M4ML+J7 M8"W8CDQ"8!,K$;#G5 M>,>#S/90,F)QDJ48:>G[/FK;..EBJRI)<4G::'M7APEY@74()VT/0RU;@(^; M.(ZZT;PZK;CH/!- V/!1Q+)!^+C#?X\XLB.HRH7:RDHX7&ZTX5KOKSZ(*,+P MRK[AXW;_/5[QU,RT>A,RJ$Y@30OY#4,K^X9_4>,HT&8J-6"+?XKD_*-U-+_L(3YN_ODL#F'-?1X%%Z">CX&4+M$6FVNS<= MG[8PHK);^+BY?]'"&"XA,7&O1J^6[&3-CQOU M_\@F:9H!62T@+EL+6#H^QY-4+3X?QQ^#O&5#HZO+:NW)/7;_LI MXS.S5TQ)Q%<@Y-VVX9[UX>O 86!4DK^1+Y6!]_M\<\,9U+P] 8ZOE#+O _N2 M7WRC&?P+4$L#!!0 ( $V+<%6?H!OPL0( .(, - >&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT M7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z// MEI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC M**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QK MRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C1 M6/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_ M-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+ M_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5 MUOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO4 M9X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM M\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/ MFD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( $V+<%67BKL

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://vyantbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm vynt-20221116.xsd vynt-20221116_lab.xml vynt-20221116_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "vynt-20221116_lab.xml" ] }, "presentationLink": { "local": [ "vynt-20221116_pre.xml" ] }, "schema": { "local": [ "vynt-20221116.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "VYNT", "nsuri": "http://vyantbio.com/20221116", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-11-16to2022-11-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://vyantbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-11-16to2022-11-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001493152-22-032664-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-032664-xbrl.zip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end